HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer.
Andrea Sartore-BianchiAlessio AmatuLuca PorcuSilvia GhezziSara LonardiFrancesco LeoneFrancesca BergamoElisabetta FenocchioErika MartinelliBeatrice BorelliFederica TosiPatrizia RaccaEmanuele ValtortaEmanuela BonoldiCosimo MartinoCaterina VaghiGiovanna MarrapeseFortunato CiardielloVittorina ZagonelAlberto BardelliLivio TrusolinoValter TorriSilvia MarsoniSalvatore SienaPublished in: The oncologist (2019)
Patients with HER2-amplified/overexpressed metastatic colorectal cancer (mCRC) harbor a driver actionable molecular alteration that has been shown in preclinical models to hamper efficacy of the anti-epidermal growth factor receptor (EGFR) targeted therapies. The present study confirmed that this molecular feature was associated with worse objective tumor response and shorter progression-free survival in response to previous anti-EGFR therapies. Moreover, it was found that the occurrence of this biomarker is unlikely to be predicted based on main clinicopathological features. Therefore, HER2 status assessment should be included in the molecular diagnostic workup of all mCRC for speedy referral to clinical trials encompassing HER2-targeted double blockade independently of previous anti-EGFR treatment.
Keyphrases
- epidermal growth factor receptor
- metastatic colorectal cancer
- tyrosine kinase
- small cell lung cancer
- advanced non small cell lung cancer
- clinical trial
- free survival
- primary care
- risk assessment
- single molecule
- mesenchymal stem cells
- combination therapy
- drug delivery
- randomized controlled trial
- cell therapy
- placebo controlled